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The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising
noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor
(VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced
to endometriosis) using bevacizumab-99mTc. The results showed that bevacizumab-99mTc imaged the lesion and support his use
for NuclearMedicine applied to gynecology. Also the results appointed that this radiopharmaceutical has a hepatobiliary excretion.
It is important to notice that the dose used was almost 0,01% of the usual dose for the bevacizumab.
1. Introduction
Endometriosis is a gynecological disease defined as the
presence of growth functional endometrium outside the
uterus [1]. This disease is associated with infertility and
incapacitating painful symptoms, including chronic pelvic
pain, dysmenorrhea, and dyspareunia [2]. It is important
to notice that approximately 11% of women did not report
any gynecologic pain symptoms [3]. It is a benign disease
but it can behave like a malignant one in terms of growing,
infiltrating, and adhering to the surrounding tissues [4].
However, the pathogenesis of endometriosis has not yet
been fully clarified. The most widely accepted theory for
the development of endometriosis is the implantation theory
of Sampson [5], who proposed that endometrial tissue is
shed in a retrograde manner into the peritoneal cavity
during menstruation, where it attaches and proliferates at
ectopic sites. In addition to the retrograde flow of exfoliated
endometrium, new blood vessels essential for the survival of
the endometrial implant, and therefore the development of
endometriosis, must be formed [6].
The pathological angiogenesis occurs in a range of
diseases that could be classed together as angiogenesis-
dependent diseases, and the endometriosis has been assigned
to this group [7]. Endometrial angiogenesis is promoted by
numerous inducers and growth factors, including vascular
endothelial growth factor (VEGF). Several authors postulated
that VEGF-induced angiogenesis is a critical aspect of the
pathophysiology of this disease [8–11].
Moreover, the endometriosis is regarded as a complex and
heterogeneous disease, which is associated with diagnosis
delay and high recurrence rates. According to the American
Congress of Obstetricians and Gynecologists, the only way
to definitively diagnose endometriosis (of any type) is direct
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visualization of the endometriotic implant by a trained
surgeon followed by biopsy and histological confirmation
as the gold standard; in any case an invasive procedure is
required [12]. As angiogenesis represents a critical step in
the establishment and pathogenesis of endometriosis; this
process has been viewed as a potential new target for better
diagnoses of disease.
Bevacizumab is a recombinant humanized monoclonal
antibody IgG1 which selectively binds to and neutralizes
the biological activity of vascular endothelial growth factor
(VEGF) and inhibits its interaction with receptors VEGFR 1
and VEGFR 2 [13]. Bevacizumab monoclonal antibody was
approved for treatment of first and second line metastatic
colorectal cancer; in combination with 5-fluorouracil, it is
also approved for the treatment of first line non-small cell
lung cancer and for unresectable, locally advanced, recurrent,
or metastatic disease [1] as well as metastatic breast cancer
when combined with carboplatin and paclitaxel. It was
recently approved (November 2014) for platinum-resistant
recurrent epithelial ovarian cancer in combination with
chemotherapy (paclitaxel, pegylated liposomal doxorubicin,
or topotecan). There is also evidence of the effectiveness of
bevacizumab as the sole medication in metastatic clear cell
renal cancer [13, 14] or combined with erlotinib [14, 15],
but it was only approved for the treatment of renal cell
carcinoma with interferon-𝛼 [16]. Finally, bevacizumab has
shown antitumour activity in glioblastoma. Based on the
improvement in objective response rate, it was approved
as a single agent in adult patients with progressive disease
following prior therapy because glioblastoma is a highly
vascularised tumour with high levels of VEGF [16, 17].
Is important to notice that there is no study of labeling
bevacizumab with 99mTc for endometriosis imaging. A good
and initial expectation for the use of antiangiogenic agents
is that they would be practically free of adverse reactions
since the dose for Nuclear Medicine procedure is almost
0,01% of the normal dose used in clinics. The aim of this
study was to evaluate the bevacizumab labelled with 99mTct
as a new, noninvasive radiopharmaceutical for diagnosis of
endometriosis.
2. Methodology
2.1. Surgical Induction of Endometriosis. The endometriosis
model was established as previously described elsewhere [10–
12, 18]. In brief, 20 female rats were opened at the abdomen
through a 3 cm midline incision to expose the uterus. One
uterine horn was ligated at both the uterotubal junction and
the cervical end and was removed. The segment was placed
in phosphate-buffered saline at 37∘C and split longitudinally,
and 5 × 5mm pieces were sectioned. These explants were
then anchored onto the peritoneum on the right side of
the ventral abdominal wall by nonabsorbable polypropylene
sutures (Prolene 6-0, Ethicon, Piscataway, NJ). The abdomen
was closed and the animals were allowed to recover from
anesthesia. After 15 days, the bevacizumab labeled with
99mTc was administered intraocularly, and the animals were
euthanized to collect the endometriotic lesions, blood, and
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Figure 1: Biodistribution of bevacizumab labeled with 99mTc after
1 hour injection. This is the mean of 15 rats.
the other organs (spleen, heart, kidney, lung, stomach, brain,
liver, and intestine).
All experiments were conducted in accordance with
the ethical guidelines from the Institutional Animal Care
Committee (CEUA) in Universidade Estadual da Zona Oeste
(UEZO) of Rio de Janeiro, Brazil, protocol code: CEUA-
UEZO.009/14.
2.2. Labeling with 99mTc and Imaging. The labeling process
was done using 150𝜇L of the bevacizumab incubated with
stannous chloride (SnCl
2
) solutions (80 𝜇L/mL) (Sigma-
Aldrich) for 20 minutes at room temperature. Then this
solution was incubated with 100 𝜇Ci (approximately 300 𝜇L)
of technetium-99m for another 10 minutes in order to label
bevacizumab with 99mTc [19, 20].
2.2.1. Quality Control of the Labeling Process. The quality
control of the labeling process was done by TLC (Thin layer
Chromatography).
2.2.2. Biodistribution. The biodistribution studies were done
with 15 rats (Wistar) (Figure 1). The final averages were used
to construct the graphics.The Institutional Review Board and
the Animal Ethics Committee approved the study protocol.
The labeled samples (3.7MBq/0.2mL) were administered by
intraocular injection. Counts were acquired for 5min in a
15% window centered at 140KeV after 1 h of the injection.
The animals were sacrificed and their organs removed and
weighed, and the radioactivity uptake is counted in a gamma
counter (Perkin Elmer). Results were expressed as a percent-
age of injected dose (activity) per gram of tissue [21].
2.2.3. Imaging. Planar images (Figure 2) were obtained at
60min after injection using a Millennium Gamma Camera
(GE Healthcare, Cleveland, USA). Counts were acquired for
5min in a 15% window centered at 140KeV. The images
were processed using OsiriX software, and regions of interest
(ROIs) over the lesion were selected for specific analysis
(Figure 1). The Institutional Review Board and the Animal
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Figure 2: Planar image of the lesion after 1 hour injection.
Ethics Committee of the Federal University of Pernambuco
(number 23076.002362/2010-37) approved all studies.
3. Results and Discussion
The labeling process showed >99% of the bevacizumab with
99mTc in interval of 24 hours. This supports the labeling
process using the direct method.
The results of biodistribution showed a high uptake of
bevacizumab-99mTc by the liver and spleen, even in the
presence of the lesion (endometriosis).Theuptake by the liver
suggests fastmetabolism of the drug, which is of great interest
for a diagnostic drug. The presence in the spleen, lung,
and intestine is explained by the fact that the mesenchyme
of the intestine and also spleen and lung of rats secretes
several ligands for epidermal growth factor that induces
differentiation of the epithelial cell sites [8].
The image showed that the lesion was well defined and
supports the use of this radiopharmaceutical for endometrio-
sis diagnosis.
The objective of this study was to determine whether
labeled monoclonal antibody anti-VEGF (bevacizumab)
could be useful in the diagnosis of endometriosis. A study [9,
10] has shown that in endometriotic implants there are a high
level of neovascularization, and in consequence a high level
of VEGF. Unfortunately, the mean latency of 6-7 years from
onset of symptoms to definitive diagnosis of endometrio-
sis may have significant consequences in terms of disease
progression. In this direction a noninvasive diagnostic tool
could be used more readily by clinicians, perhaps leading to
decreased time until diagnosis and subsequently decreased
consequences due to disease progression [22]. In addition,
the laparoscopy, the invasive procedure surgery, remains the
gold standard approach to diagnostic endometriosis and the
lack of a laboratory biomarker for the disease remains a
top research priority. The discovery of a sufficiently sensitive
and specific clinical agent for the nonsurgical detection of
endometriosis promises earlier diagnosis in order to provide
additional support for treatment planning. Also the develop-
ment of new radiopharmaceutical that could be used daily in
the clinic routine is quite promising.
4. Conclusion
The results showed that bevacizumab labeled with 99mTc
may be supported to be used as radiopharmaceuticals for
endometriosis imaging, instead of surgical procedure. This
study is just a preliminary one and further studies are
required, especially a cost-effective one, in order to show the
real advantages in terms of cost of the use of bevacizumab-
99mTc since the monoclonal antibody is still expensive.
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